Thermo Fisher Scientific Inc
11 nominees · 3 ballot items.
Election of 11 directors; advisory (non-binding) vote to approve executive compensation (say-on-pay), including a CEO retention grant; and ratification of PricewaterhouseCoopers LLP as independent auditors.
Follow how the vote landed and what changed on Thermo Fisher Scientific Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
Election of directors
ManagementBoard: FORElect 11 director nominees to serve until the 2027 Annual Meeting (Board size reduced to 11; one director not seeking re-election).
- 2
Approval of an advisory vote on executive compensation
ManagementBoard: FORNon-binding advisory approval of the compensation of named executive officers, including support for the CEO retention grant approved in May 2025.
More detail
This management proposal asks shareholders to cast a non-binding advisory vote approving the Company’s executive compensation as disclosed in the CD&A and related tables, including substantive elements such as the 2025 CEO retention grant. Management frames the vote as a mechanism for shareholders to express support or concerns; although advisory, the Compensation Committee and Board commit to considering the outcome in future program design. Context includes a low prior-year say-on-pay result (36% support in 2025) that prompted extensive shareholder engagement and resulted in multiple program changes for 2026 (e.g., shifting PRSUs to 3-year metrics, increasing PRSU weight to 50% of LTI for all NEOs, and other disclosure improvements). Notable contested aspects include the large, off-cycle CEO retention grant approved in May 2025 (141,538 PRSUs at target, cliff vesting in May 2030, payout based on TSR vs. the S&P 500 with cap if absolute TSR is negative, and deferred delivery through 2033–2035) and the Compensation Committee’s rationale that the grant was necessary to retain CEO leadership through strategic transitions and a CFO change. The Board recommends voting FOR the proposal, arguing the plan changes made in response to shareholder feedback, the retention grant’s performance-based structure, and governance protections (clawbacks, holding requirements, consultant input) align management incentives with long-term shareholder value. Investors should weigh whether the structural changes meaningfully address concerns that led to the low prior support, whether the retention grant’s size and terms are proportionate to the retention risk, and how future compensation outcomes may interact with realized TSR and company performance.
- 3
Ratification of the selection of the independent auditors
ManagementBoard: FORRatify the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2026.
More detail
This proposal seeks shareholder ratification of the Audit Committee’s selection of PwC to serve as the Company’s independent auditors for 2026. Management emphasizes continuity and PwC’s institutional knowledge since serving as auditors since 2002, and describes Audit Committee oversight practices and independence controls, including lead partner rotation and formal pre-approval of audit and non-audit services. The Audit Committee asserts ratification is in shareholders’ interest due to audit quality, operational efficiencies, and cost avoidance related to auditor transition; however, it notes that even if not ratified the Committee may reconsider the selection. The Board recommends FOR ratification to support the auditing process and signals confidence in PwC’s qualifications and independence.
Nominees on the ballot11
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.5% | 24,280,816 | $11.9B |
| 2 | STATE STREET CORP | 4.5% | 16,731,668 | $8.2B |
| 3 | BlackRock, Inc. | 2.6% | 9,721,037 | $4.8B |
| 4 | BlackRock, Inc. | 2.1% | 7,650,800 | $3.8B |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.9% | 7,199,294 | $3.5B |
| 6 | Capital World Investors | 1.8% | 6,646,316 | $3.3B |
| 7 | FMR LLC | 1.8% | 6,625,522 | $3.3B |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7% | 6,163,370 | $3.0B |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 5,771,154 | $2.8B |
| 10 | MORGAN STANLEY | 1.5% | 5,674,396 | $2.8B |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Thermo Fisher Scientific Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Thermo Fisher Scientific Inc 2026 annual meeting?
- Thermo Fisher Scientific Inc (TMO) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.
- What is the record date for the Thermo Fisher Scientific Inc 2026 meeting?
- The record date for the Thermo Fisher Scientific Inc 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Thermo Fisher Scientific Inc's 2026 meeting?
- The board is presenting 11 director nominees at the Thermo Fisher Scientific Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Thermo Fisher Scientific Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Thermo Fisher Scientific Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.